Plasma Levels of β-Amyloid(1-40), β-Amyloid (1-42), and Total β-Amyloid Remain Unaffected in Adult Patients with Hypercholesterolemia after Treatment with Statins

Archives of Neurology

Volumn 61, Issue 3, 2004, Pages 333-337

  Höglund, Kina ^a,e   Wiklund, Olov ^b   Vanderstichele, Hugo ^c   Eikenberg, Oliver ^d   Vanmechelen, Eugeen ^c   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c INNOGENETICS   (Belgium)

^d ABETA GmbH   (Germany)

^e Institute of Clinical Neuroscience   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ATORVASTATIN; CHOLESTEROL; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OUTCOMES RESEARCH; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UNIVERSITY HOSPITAL; WESTERN BLOTTING;

ADULT; AGED; AMYLOID BETA-PROTEIN; ANTICHOLESTEREMIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PYRROLES; SIMVASTATIN; TIME FACTORS;

EID: 12144290725     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.3.333     Document Type: Article

References (35)

1. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 1992;359:325-327.
2. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
3. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46:412-416.
4. Giubilei F, D'Antona R, Antonini R, et al. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand. 1990;81:84-86.
5. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995;45:1092-1096.
6. Poirier J. Apolipoprotein E and Alzheimer's disease: a role in amyloid catabolism. Ann N Y Acad Sci. 2000;924:81-90.
7. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
8. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E € 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20.
9. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
10. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
11. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
12. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856-5861.
13. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464.
14. Sparks DL, Kuo YM, Roher A, et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann N Y Acad Sci. 2000;903:335-344.
15. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
17. Kabara JJ. A critical review of brain cholesterol metabolism. Prog Brain Res. 1973;40:363-382.
18. Lutjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A. 1996;93:9799-9804.
19. Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27-32.
20. Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003;60:510-515.
21. Locatelli S, Lutjohann D, Schmidt HH, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol. 2002;59:213-216.
22. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002;251:338-347.
23. Illingworth DR, Crouse JR 3rd, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50.
24. (1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245-258.
25. (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673-680.
26. Zlokovic BV. Cerebrovascular transport of Alzheimer's amyloidβ and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996;59:1483-1497.
27. Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J Biol Chem. 1995;270:7563-7567.
28. Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem. 1996;271:32916-32922.
29. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002;59:1257-1258.
30. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 2003;16:25-30.
31. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-350.
32. Buxbaum JD, Cullen El, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients. Front Biosci. 2002;7:a50-a59.
33. Frears ER, Stephens DJ, Walters CE, et al. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport. 1999;10:1699-1705.
34. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
35. Mehta PD, Pirttila T, Patrick BA, et al. Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102-106.